Flare

Boehringer Ingelheim, Fashion Institute of Technology's DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease

Retrieved on: 
Wednesday, June 28, 2023
Interactive media, Flare, Collection, User experience design, Partnership, Fashion Institute of Technology, Heart failure, Life, Hospital, Face, Anxiety, FIT, Quality of life, Kidney, Fashion design, Individual, Innovation, Element, Hess, Marketing, Sepsis, Pain, Boehringer Ingelheim, Fashion, Congress, Student, Beauty, Assistant professor, Art, Exhibition, Faculty, Paper, Digital, GPP, Creative director, Death, Glass, Animation, Disease, Nursing, Toy, Uncertainty, Dermatology

"Since its introduction last year, The Unwearable Collection has helped to raise much-needed awareness for GPP.

Key Points: 
  • "Since its introduction last year, The Unwearable Collection has helped to raise much-needed awareness for GPP.
  • Trapped by Uncertainty combines unwearable elements, such as shards of glass and crystals, with materials used in everyday fashion design.
  • FIT's Fashion Design team worked under the supervision of Dobriana Gheneva, Assistant Professor, Fashion Design, with creative direction by Michael Ferraro, Executive Director, FIT DTech Lab to create the fifth design.
  • "It was the experiences of people living with GPP and their descriptions of the disease that ultimately inspired me to create The Unwearable Collection.

Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-515 in Lupus

Retrieved on: 
Tuesday, June 27, 2023
Transfer, Optic neuritis, Lupus, Flare, STTR, Cancer, End organ damage, Research, Brain, SLE, Biomarker, Investigational New Drug, Patient, Disease, Diagnosis, Mortality, NIAID, UCLA, National Institute of Allergy and Infectious Diseases, IND, NIH, Infection, Autoimmunity, Pharmaceutical industry

The grant will fund Investigational New Drug (IND) enabling activities using TRE-515 to treat systemic lupus erythematosus (SLE), a chronic autoimmune disease with significant morbidity and mortality.

Key Points: 
  • The grant will fund Investigational New Drug (IND) enabling activities using TRE-515 to treat systemic lupus erythematosus (SLE), a chronic autoimmune disease with significant morbidity and mortality.
  • Trethera’s lead asset, TRE-515, is a first-in-class deoxycytidine kinase (dCK) inhibitor.
  • "The potential TRE-515 has to treat a broad spectrum of diseases creates a pipeline in a product that reduces overall development risk," said Dr. Ken Schultz, principal investigator and Trethera CEO.
  • “We are grateful that the NIH also recognizes this, providing $4.2M in overall grant funding since September for optic neuritis, solid tumors, and now lupus.

KES China Facility Operational, Driving Localization and Embracing Chinese Market

Retrieved on: 
Monday, June 12, 2023
Carbon, Dual carbon battery, Maintenance, Flare, Food, KES, Industrialisation, Congress Working Committee, Steel, Koch Industries, Renewable energy, ET, Iron, Engineering, Digital China, Growth, Automation

With its entry into the Chinese market in the 1980s, KES has been dedicated to technology licensing, combustion and emission control, mass and heat transfer, separation and digital solutions.

Key Points: 
  • With its entry into the Chinese market in the 1980s, KES has been dedicated to technology licensing, combustion and emission control, mass and heat transfer, separation and digital solutions.
  • The 60,000-square-meter facility is KES' first wholly owned facility in China and is located in the Changshu Economic & Technological Development Zone.
  • With over 40 years of experience in the Chinese market, KES possesses a profound understanding of the sector's opportunities and challenges.
  • Moreover, the strategic investment deepens KES' localization initiatives and strengthens its ties with the Chinese market.

Novartis premieres powerful new docuseries at Tribeca Festival to shine a light on debilitating skin disease

Retrieved on: 
Thursday, June 8, 2023
Flare, Disease, Partnership, Depression, Life, Scar, Woman, Pain, HS, Hidradenitis suppurativa, The Beacon School, Novartis, Rheumatology, EAST, Tribeca Festival, Diagnosis, Shine a Light, Skin, Television, Film industry, Birth control

The docuseries, co-produced with and hosted by HS advocate, journalist and filmmaker Jasmine IVANNA Espy, highlights the experiences of people from multiple countries living with HS.

Key Points: 
  • The docuseries, co-produced with and hosted by HS advocate, journalist and filmmaker Jasmine IVANNA Espy, highlights the experiences of people from multiple countries living with HS.
  • HS is characterized by recurring boil-like lumps that can burst into open wounds, which may result in irreversible scarring.
  • The new docuseries is part of the "Shine a Light on HS" campaign, which was developed by Novartis to help educate and provide helpful tools to people who are undiagnosed but suffering from the symptoms of HS.
  • To watch the docuseries and learn more about HS, US audiences can visit ShineALightOnHS.com .

12 Steps to A Great Road Trip

Retrieved on: 
Wednesday, June 7, 2023
Chocolate, Insurance, Checklist, Pressure, Maintenance, Lincoln, Flare, ID, GPS, Atlas, Travel, Erie Insurance Group, Snack, Rest, Vegetable, Water, Tourism, Satellite navigation device, Rail transport

Erie Insurance has 12 tips to help make your next road trip memorable — and prepare for whatever may come your way.

Key Points: 
  • Erie Insurance has 12 tips to help make your next road trip memorable — and prepare for whatever may come your way.
  • Even though you haven't used one in ages, keeping a road atlas in the car is always a good idea.
  • When it comes to packing for your road trip, we know the people you travel with are your most important cargo.
  • Whether you're taking an epic road trip or going just across town, we've got you covered.

New Real-World Evidence from Personalized Trials Calls for Rethinking the Standard of Care for Non-Responders to Autoimmune Therapies

Retrieved on: 
Thursday, June 1, 2023
Nutrition, Flare, Food, Elijah Cummings Lower Drug Costs Now Act, Rx, Arthralgia, Health, COVID-19, IBD, Anxiety, MCTD, Quality of life, Weakness, Ankylosing spondylitis, Rheumatology, Research, SLE, COVID, Lupus, Movement, Psoriasis, Fatigue, Myalgia, Excipient, WAC, Disease-modifying antirheumatic drug, Oscar Health, Johns Hopkins University, Mount Sinai Hospital, Patient, Physician, Risk, Population health, Quality of life (healthcare), UHC, Observation, Climate, American College, Allergen, Autoimmunity, Rheumatoid arthritis, Factorization of polynomials, Pharmaceutical industry, Medical device

NEW YORK, June 1, 2023 /PRNewswire/ -- Today Mymee Inc, a pioneer in personalized trials & care for patients with uncontrolled autoimmune and long COVID disease flares, announced new peer-reviewed and payer-audited research that sheds light on the enormous challenges facing autoimmune patients with joint flares, >30 moderate to high frequency symptoms, and inadequate response to pharmacological treatments.

Key Points: 
  • Findings explain why rheumatic patients are successfully able to reverse flares through personalized trials and care.
  • Average autoimmune biologic and targeted therapy reductions reported in the study were validated through an independent analysis by a commercial insurer.
  • It is clear industry stakeholders should take steps to improve the standard of care for this overlooked patient population."
  • In the interim, this study demonstrates it's possible for personalized trials & care to help patients gain control of their flares and reclaim their health, when the standard of care fails them."

Axuall Secures $20 Million Series B Capital Raise after Accelerated Market Growth and Healthcare Enterprise Adoption

Retrieved on: 
Wednesday, May 31, 2023
Marketing, EVP, API, Intelligence, Organization, Friction, Flare, Credentialing, CRM, Humble Bundle, Ecosystem, Health, ROI, Nursing

“Timely clinician population data is key to optimizing a healthcare workforce, a factor that ranks among the most critical priorities for healthcare leaders,” stated Ajay Kumar, M.D., EVP & Chief Clinical Officer, Hartford HealthCare.

Key Points: 
  • “Timely clinician population data is key to optimizing a healthcare workforce, a factor that ranks among the most critical priorities for healthcare leaders,” stated Ajay Kumar, M.D., EVP & Chief Clinical Officer, Hartford HealthCare.
  • Planning, recruiting, and placement have long been inefficient, time-consuming, and painful for clinicians and healthcare organizations.
  • However, organizations that leverage data networks to streamline the process will be the choice of healthcare systems and clinicians in the coming years.
  • “We are humbled and honored by the support from the healthcare community and forward-looking investors as we address this opportunity to improve access to quality care.”

First Ever Study of RA Patient Attitudes on Bloodwork to Predict Future Treatment Presented by CreakyJoints

Retrieved on: 
Wednesday, May 31, 2023
Research, Clinical Trials, Communications, Health Technology, Telemedicine, Virtual Medicine, Managed Care, Social Media, General Health, Health, Science, Online, Exercise, Communication, Medical Affairs Bureau, Psoriatic arthritis, RA, Probability, Flare, Arthritis, European Alliance of Associations for Rheumatology, Sleep, Social media, Utility, C-reactive protein, Pulse, Cross, Pain, Uric acid, CRP, MD, Patient, Swelling, CEST, Rheumatoid arthritis, Diagnosis, EULAR, MPH, European Alliance, Conditional sentence, Pharmaceutical industry, Nursing, Rheumatology, Doctor of Philosophy, Gout

Most patients understood that their doctor ordered laboratory tests to check for active inflammation (85.9%) or assess side effects of medications (81.2%).

Key Points: 
  • Most patients understood that their doctor ordered laboratory tests to check for active inflammation (85.9%) or assess side effects of medications (81.2%).
  • Most feared (91.4%) that their current RA medication would stop working and that they would waste time trying to find (81.7%) an alternative, effective therapy.
  • “This study demonstrates that patients understand the value of bloodwork, even when they may not fully comprehend how to interpret results and apply them to decisions about care and treatment.
  • Moreover, people living with RA worry about the trial and error process of RA treatment, especially if it means wasting time on a new medication that doesn’t work for them.

New Report from East Daley Analytics and Validere Highlights How Operators Can Manage Greenhouse Gas Emissions from Flares

Retrieved on: 
Tuesday, May 23, 2023
Other Energy, Environment, Oil, Gas, Environmental Issues, Energy, Climate Change, Permian, Methane, CO2, Delays, MRV, Software as a service, Flare, Attention, Cost, Global warming potential, Natural gas

East Daley Analytics and Validere , a measurement, reporting, and verification ( MRV ) SaaS company, released a new report: Emissions Critical: Flaring, Methane, and the Cost of Looming Permian Gas Takeaway Constraints .

Key Points: 
  • East Daley Analytics and Validere , a measurement, reporting, and verification ( MRV ) SaaS company, released a new report: Emissions Critical: Flaring, Methane, and the Cost of Looming Permian Gas Takeaway Constraints .
  • Permian Basin flaring caught the attention of governments, investors, and consumers in 2019 as natural gas transmission capacity lagged the associated gas production coming along with explosive oil production growth.
  • Another round of infrastructure projects is now under construction, but Permian production growth again looks set to exceed this pipeline build-out.
  • “With Permian flaring levels likely to rise, operators in the basin will face increased environmental scrutiny,” said Jen Snyder, senior advisor at Validere.

Cimarron announces strategic partnership with JATCO to offer all-in-one solution for BTEX and emissions control

Retrieved on: 
Monday, May 22, 2023
Shell, Flare, Partnership, Cimarron Fuel Fabrication Site, DRE, BTEX, Dehydration, Volatile organic compound, VOC, SOX, NOX, Greenhouse gas, EPA, Soil, Water, Natural gas, Methane, Transport, Environment, Environmental remediation, Renewable energy

HOUSTON, May 22, 2023 /PRNewswire-PRWeb/ -- Cimarron, Inc. ("Cimarron"), a leading provider of environmental control and process equipment for the energy and biogas industries, and JATCO, Inc. ("JATCO"), a manufacturer of BTEX environmental solutions for the oil and gas production and transportation industries, announced today that they have established a strategic partnership to offer an all-in-one solution for BTEX and emissions control. The partnership will enable both companies to leverage their respective strengths and expertise in providing cost-effective, reliable, and innovative solutions that recovers methane back to the value stream.

Key Points: 
  • By partnering with JATCO, Cimarron is now offering both natural and forced-draft types of heat exchangers coupled with high efficiency combustors to capture and destruct these VOCs.
  • HOUSTON, May 22, 2023 /PRNewswire-PRWeb/ -- Cimarron, Inc. ("Cimarron"), a leading provider of environmental control and process equipment for the energy and biogas industries, and JATCO, Inc. ("JATCO"), a manufacturer of BTEX environmental solutions for the oil and gas production and transportation industries, announced today that they have established a strategic partnership to offer an all-in-one solution for BTEX and emissions control.
  • "By offering a one-stop shop, customers benefit with a best-in-class solutions, JATCO's BTEX systems with Cimarron's EPA-certified combustors, for their environmental control needs."
  • Our solutions include cost-effective, reliable equipment designed to prevent soil, water, and atmospheric pollution," said Scott Hill, President of JATCO.